^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors

Published date:
01/20/2022
Excerpt:
WBC100 Potently Regresses c-Myc Overexpressing Solid Tumors In Vivo...therapeutic effects of WBC100 on c-Myc overexpressing pancreatic ductal adenocarcinoma (PDAC)…Treatment with 0.1, 0.2, and 0.4 mg kg–1 doses of WBC100 resulted in 71.94%, 87.63%, and 96.14% of tumor growth inhibition (TGI), respectively...WBC100 potently regresses c-Myc overexpressing human pancreatic ductal adenocarcinoma (PDAC) in nude mice...
DOI:
https://doi.org/10.1002/advs.202104344